ArticleNature communications2021
De novo biosynthesis of bioactive isoflavonoids by engineered yeast cell factories.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 151 citations in OpenAlex.
- Functional identification of key enzymes in calycosin biosynthesis inPharmaceutical science advances · 2026Article
- Structural insights into a dual-substrate O-methyltransferase reveal the enzymatic mechanism of parallel paeonol biosynthesis.Nature communications · 2026Article
- Yeast species resource exploration and application in cell factories.Synthetic and systems biotechnology · 2026Review
- Bridging Biosynthesis and Bioavailability: Integrated Strategies for Tailoring Soybean Isoflavone Profiles.Comprehensive reviews in food science and food safety · 2026Review
- Biological applications and future perspectives of bioactive compounds as pig feed additives.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2026Review
- Metabolic Engineering Strategies for Flavonoid Biosynthesis in Saccharomyces cerevisiae: Current Advances and Future Perspectives.Biotechnology and bioengineering · 2026Review
- Engineered microorganisms unlock a new era of diterpenoid biomanufacturing: recent advances and future perspectives.Bioresources and bioprocessing · 2026Review
- High yield strategies for triterpenoid biosynthesis in cell factories.Journal of microbiology (Seoul, Korea) · 2026Review
- Block-building with yeast to elucidate an artificial pathway for de novo biosynthesis of glabridin.Nature communications · 2026Article
- Toward sustainable food preservatives: high-level production of sorbic acid in engineered Saccharomyces cerevisiae.Nature communications · 2026Article
- Article
- Structure-Guided Engineering of a Promiscuous O-Methyltransferase for a SAM Regeneration Biocatalysis Platform of Methylated Pharmaceuticals.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Engineering Saccharomyces cerevisiae to improve heterologous abscisic acid production.Microbial cell factories · 2026Article
- Metabolic Engineering ofChem & bio engineering · 2026Article
- Efficient, complete biosynthesis of isoflavonoid calycosin-7-glucoside by metabolically engineered yeast cell factories.Frontiers in bioengineering and biotechnology · 2026Article
- Advanced applications of synthetic biology technology in biosynthesis of bioactive compounds from medicinal plants.Chinese herbal medicines · 2026Review
- De novo biosynthesis ofBiodesign research · 2025Article
- Engineering yeast peroxisome assembly enables the increased production of acetyl-CoA and its derived 5-deoxyflavonoids.Nature communications · 2025Article
- Recent Advances in Biosynthesis Technology and Future Functional Foods.Foods (Basel, Switzerland) · 2025Article
- Glyceollin biosynthesis in a plant chassis engineered for isoflavone production.Nature chemical biology · 2025Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isoflavonoids comprise a class of plant natural products with great nutraceutical, pharmaceutical and agricultural significance. Their low abundance in nature and structural complexity however hampers access to these phytochemicals through traditional crop-based manufacturing or chemical synthesis. Microbial bioproduction therefore represents an attractive alternative. Here, we engineer the metabolism of Saccharomyces cerevisiae to become a platform for efficient production of daidzein, a core chemical scaffold for isoflavonoid biosynthesis, and demonstrate its application towards producing bioactive glucosides from glucose, following the screening-reconstruction-application engineering framework. First, we rebuild daidzein biosynthesis in yeast and its production is then improved by 94-fold through screening biosynthetic enzymes, identifying rate-limiting steps, implementing dynamic control, engineering substrate trafficking and fine-tuning competing metabolic processes. The optimized strain produces up to 85.4 mg L
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.